Real world evidence stories

Oct 23, 2026

Real-world study confirms Lu-PSMA-617 benefits for metastatic prostate cancer patients

Results from France's early-access program demonstrate that PSMA-targeted radiopharmaceutical therapy Lu-PSMA-617 is safe and effective for patients with metastatic castration-resistant prostate cancer in routine clinical practice, confirming findings from controlled trials.

Oct 23, 20264 sources

Sep 9, 2026

Semaglutide linked to 40% reduction in asthma attacks in large real-world study

A large observational study found semaglutide (Ozempic/Wegovy) was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups compared to other treatments.

Sep 9, 20262 sources

Top claims

▪Prostate cancer mortality after four years was 5% among DASL-HiCaP trial participants treated with darolutamide compared to 14% among participants given a placebo.
▪Johnson & Johnson presented early-stage clinical trial data showing its experimental oral prostate cancer drug JNJ-6143 produced PSA reductions of at least 50% in 77% of evaluable patients at a 50-mg dose.
▪In the 1,106-patient DASL-HiCaP trial, 95% of patients receiving darolutamide had not developed metastatic prostate cancer after four years compared to 88% of patients receiving a placebo.

Subtopics

Cancer & Oncology1 Cancer research1 Cancer treatment1 Cancer Treatment & Therapies1 Drug Approval and Clinical Trials1 Drug Policy, Pricing & Approval1 Evidence based supplementation1 GLP-1 / Weight-Loss Medications1 GLP-1 medications1 Lifestyle, Wellness and Nutrition1 Oncology1 Patient access1 Respiratory health1 Supplementation1 Targeted cancer therapy1 Weight loss medications & GLP-1 drugs1 Weight management1

Related timelines